Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07449039

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.

Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gestational Diabetes Mellitus in Pregnancy

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of California, Los Angeles

Los Angeles, California, 90095, United States

Location status: Recruiting

Location contact

Dana Levin-Lopez, MPH

CONTACT

[email protected]

310-794-8893

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prenatal care at UCLA Health
  • Planning to deliver at UCLA Ronald Reagan or UCLA Santa Monica
  • Confirmed gestational diabetes diagnosis based on 2-step approach
  • Maternal age >= 18 years

Exclusion criteria

  • Pre-gestational diabetes (T1DM or T2DM)
  • Multifetal gestation
  • Intra-amniotic infection by clinical criteria
  • Postpartum hemorrhage
  • Maternal ICU admission
  • Known allergy to medical-grade adhesive
  • Presence of skin lesions at anticipated CGM application site
  • Scheduled postpartum non-sonographic imaging study (radiograph, magnetic resonance imaging (MRI), or computed tomography (CT) scan) during trial
  • Metformin use
  • Steroid use
  • Terbutaline use within 4 hours of delivery
  • Cystic fibrosis
  • MODY (mature onset of diabetes in the young)

Treatment and study plan

Continuous Glucose Monistor

Device

Continuous glucose monitoring sensor that provides 24/7 detailed glycemic information. Participants will wear for 24 hours and then be instructed to peel off.

Other names: Dexcom G7

Primary outcomes

  1. Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test

    Time frame: 24 hours postpartum and 1-3 months postpartum

    Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT

  2. Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum

    Time frame: 24 hours postpartum and 1-3 months postpartum

    Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c

Secondary outcomes

  1. Patient satisfaction with CGM use immediately postpartum to evaluate long term risk

    Time frame: 1-3 months postpartum after glucose tolerance test, 12-24 months postpartum after A1C blood test

    Patient satisfaction will be measured via survey response on following statements using 5 point likert scale

    • Applying the CGM was painless.
    • Applying the CGM was easy.
    • Wearing the CGM for 24 hours postpartum was painless.
    • Wearing the CGM for 24 hours postpartum was easy.
    • Wearing the CGM did not interfere with my activities of daily living.
    • Wearing the CGM did not cause any side effects.
    • Removing the CGM was painless.
    • Removing the CGM was easy.
    • If given a choice between the 1-3 month postpartum OGTT and wearing the CGM for 24 hours immediately postpartum, I would choose wearing the CGM.

Study contacts

Contact information is provided by the study sponsor or research team.

Dana Levin-Lopez, MPH

CONTACT

[email protected]

310-794-8893

Rujuta Sathe

CONTACT

[email protected]

310-794-8893

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Registry information

Acronym: POSTPOD

Important dates

Study start
2025
Primary completion
2029
Study completion
2030
First posted
Mar 4, 2026
Registry last updated
Mar 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.